Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Tendera

Showing results (91-100 of 131) with videos related to

Pageof 14
Sort By:
Circulation|September 24, 2004
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialFranz Hartmann, Milton Packer, Andrew J S Coats, et al.
American Heart Journal|March 30, 2013
Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarctionAnjan K Chakrabarti, Kristin Feeney, Cassandra Abueg, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) studyFrancesco Prati, Sonia Petronio, Ad J Van Boven, et al.
Journal of Clinical Medicine|December 22, 2019
Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY RegistryEmmanuelle Vidal-Petiot, Nicola Greenlaw, Paul R Kalra, et al.
American Heart Journal|June 17, 2004
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarctionPeter R Sinnaeve, John H Alexander, Kris Bogaerts, et al.
Circulation|October 23, 2002
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyMilton Packer, Michael B Fowler, Ellen B Roecker, et al.
Journal of Molecular Medicine (Berlin, Germany)|April 28, 2005
Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathyAndreas Perrot, Hajo Schmidt-Traub, Bernard Hoffmann, et al.
European Heart Journal|November 21, 2015
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary interventionC Michael Gibson, Robert P Giugliano, Robert A Kloner, et al.
Clinical Chemistry|January 8, 2017
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 TrialAlon Eisen, Marc P Bonaca, Petr Jarolim, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Pageof 14

Showing results (91-100 of 131) with videos related to

Sort By:
Pageof 14
Circulation|September 24, 2004
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialFranz Hartmann, Milton Packer, Andrew J S Coats, et al.
American Heart Journal|March 30, 2013
Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarctionAnjan K Chakrabarti, Kristin Feeney, Cassandra Abueg, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) studyFrancesco Prati, Sonia Petronio, Ad J Van Boven, et al.
Journal of Clinical Medicine|December 22, 2019
Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY RegistryEmmanuelle Vidal-Petiot, Nicola Greenlaw, Paul R Kalra, et al.
American Heart Journal|June 17, 2004
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarctionPeter R Sinnaeve, John H Alexander, Kris Bogaerts, et al.
Circulation|October 23, 2002
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyMilton Packer, Michael B Fowler, Ellen B Roecker, et al.
Journal of Molecular Medicine (Berlin, Germany)|April 28, 2005
Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathyAndreas Perrot, Hajo Schmidt-Traub, Bernard Hoffmann, et al.
European Heart Journal|November 21, 2015
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary interventionC Michael Gibson, Robert P Giugliano, Robert A Kloner, et al.
Clinical Chemistry|January 8, 2017
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 TrialAlon Eisen, Marc P Bonaca, Petr Jarolim, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Pageof 14